a-Thrombin (thrombin) stimulates phospholipase C and modulates the activity of adenylate cyclase in a number of cell types via G protein-coupled receptors. It is also a potent growth factor, notably for a line of hamster fibroblasts (CCL39 cells). Recently, predicted amino acid sequences for human and hamster thrombin receptors have been reported that display a putative thrombin cleavage site in the N-terminal extracellular domain. Synthetic peptides corresponding to 14 residues carboxyl to the presumed thrombin cleavage site of the human receptor have been shown to activate platelets as well as the thrombin receptor expressed in Xenopus oocytes. In the present study we have examined the effects of synthetic peptides corresponding to the same region of the hamster receptor (S-42-L-55) and shorter peptides (2-7 residues) on signal transducing systems in CCL39 cells. Our results indicate that hamster receptor peptides of >5 residues effectively stimulate phospholipase C in CCL39 cells via the thrombin receptor and induce rapid desensitization of the response. The same peptides also inhibit adenylate cyclase in a pertussis toxin-sensitive manner. Although the peptides are potent agonists of serotonin release in platelets, unlike thrombin, by themselves they are not mitogenic. However, they potentiate DNA synthesis in cooperation with growth factors possessing tyrosine kinase receptors. Hence, we conclude that the potent mitogenic action of thrombin cannot be accounted for solely by the activation of the cloned receptor. We postulate the existence of an additional receptor activated by thrombin, which is required for its full mitogenic potential.
INTRODUCTION
During blood coagulation, activation of the circulating zymogen prothrombin results in generation of the serine protease a-thrombin (thrombin), which in turn participates in a number of events central to hemostasis and injury repair. In addition to the proteolytic conversion of fibrinogen to insoluble fibrin, thrombin has been shown to exert multiple cellular effects (for review, see Fenton, 1988) . Many of these effects on cells, including platelets, endothelial cells, vascular smooth muscle cells, and fibroblasts, involve guanine nucleotide regulatory proteins (G proteins). Recently, amino acid sequences of functional thrombin receptors from human (Vu et al., 1991) and Chinese hamster (Rasmussen et al., 1991) © 1992 by The American Society for Cell Biology cell lines were deduced by cDNA cloning. The thrombin receptor is a member of the multigene family of seventransmembrane-domain receptors that transmit signals from quite structurally diverse ligands (Dohlman et al., 1991) . In the case of thrombin, receptor activation appears to occur through a unique mechanism whereby specific cleavage of the N-terminal ectodomain of the receptor results in the appearance of a new N-terminal sequence that functions as a built-in ligand. Evidence for this mechanism includes the observations that 1) most of thrombin's cellular effects, such as platelet activation (Davey and Luscher, 1967) and stimulation of fibroblast growth (Van , require the enzyme to be proteolytically active and 2) synthetic peptides corresponding to the human receptor sequence after the putative cleavage site can activate human platelets as well as the cloned receptor expressed in Xenopus oocytes (Vu et al., 1991) . Several questions remain to be answered concerning the nature of the signal transducing pathways coupled to the cloned receptor and the possibility that multiple receptor isoforms may exist with similar or yet different modes of activation. Furthermore, it is not clear whether the N-terminal receptor fragment released after thrombin cleavage is physiologically active or whether its sole function is to mask the "receptor-ligand."
In the present study we have analyzed the effects of several synthetic peptides corresponding to sequences of both the human and hamster thrombin receptors on a line of Chinese hamster fibroblasts (CCL39 cells) in which thrombin activation of intracellular signaling pathways and cell growth has been well characterized (for reviews, see Pouyssegur et al., 1988; Pouyssegur and Seuwen, 1992) . In these cells, growth stimulation by thrombin is sensitive to the action of pertussis toxin (Chambard et al., 1987) , implicating the involvement of one or more G protein-coupled pathways in this effect. Our results show that the receptor peptides induce serotonin release in platelets and activate G proteincoupled pathways in CCL39 cells but they do not stimulate DNA synthesis reinitiation. These findings support the idea that activation of the protein kinase C pathway can lead to stimulation of early mitogenic events, which is insufficient for cell cycle progression of resting cells (Seuwen et al., 1990a,b; Van Obberghen-Schilling et al., 1991) .
MATERIALS AND METHODS Materials
Peptides (>95% pure) were synthesized by NEOSYSTEM (Strasbourg, France). Sequences corresponding to the hamster thrombin receptor are SF-amide (2-mer), SFF (3-mer), SFFL (4-mer), SFFLR (5-mer), SFFLRN (6-mer), SFFLRNP (7-mer), and SFFLRNPGENTFEL (14-mer). The human thrombin receptor peptide sequence is SFLL-RNPNDKYEPF (14-mer). Peptides of 2, 5, 6, 7, and 14 residues were dissolved in a N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES)-buffered (20 mM HEPES, pH 7.4) Dulbecco's modified Eagle's medium (DMEM). The three-and four-residue peptides were dissolved in dimethyl sulfoxide then diluted with HEPES-buffered DMEM; the concentration of dimethyl sulfoxide never exceeded 0.6% in experiments. Highly purified human a-thrombin (3200 NIH units/ mg) and human recombinant basic fibroblast growth factor (FGF) were generous gifts of Drs. J.W. Fenton II (New York State Department of Health, Albany, NY) and D. Gospodarowicz (University of California Medical Center, San Francisco, CA), respectively. 5-Hydroxy(side chain-2-14C)-tryptamine creatine sulphate, (Myo-(2-3H)-inositol, (3H)-adenine, and (methyl-3H)-thymidine were from Amersham (Les Ullis, France); prostaglandin El, apyrase, forskolin, isobutylmethylxanthine, pertussis toxin, and fatty acid-free bovine serum albumin were purchased from Sigma (St. Louis, MO).
Serotonin Release
Whole blood was collected from healthy volunteers and anticoagulated with an acid/citrate/dextrose solution. Platelet-rich plasma was prepared immediately by low speed centrifugation (120 X g, 10 min) and platelets were separated from plasma by centrifugation (1000 X g, 10 96 min), then washed twice in citrate buffer (103 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM glucose, 36 mM citric acid, 0.35% bovine serum albumin, pH 6.5) containing 1 uM prostaglandin E1 and 25 Mug/ml apyrase. Washed platelets were resuspended (0.5 X 109 platelets/ml) in HEPES-buffered DMEM (20 mM HEPES, pH 7.4) containing 0.1% bovine serum albumin and "4C-serotonin (0.5 MCi/ ml, 10 NM). After '4C-serotonin loading (1 h, 37°C) platelets were washed three times and resuspended (4 X 10' platelets/ml) in the same medium without serotonin. Serotonin release was initiated by addition of agonist in a final volume of 100 ul and terminated after 3 min at room temperature by addition of 100 Ml of a stop solution (20 mM EDTA, 3% formaldehyde). Platelets were pelleted by centrifugation for 2 min in an eppendorf centrifuge and the radioactivity in an aliquot of supematant was determined in a # scintillation counter.
Cell Culture
The Chinese hamster fibroblast line CCL39 (American Type Culture Collection, Rockville, MD) was cultivated in DMEM containing 7.5% fetal calf serum, penicillin (50 units/ml), and streptomycin (50 Mg/ ml) at 370C in 5% CO2. To obtain growth-arrested cells, serum was removed from culture medium for 24 h.
Measurement of Phosphoinositide Breakdown
Confluent cells, in 12-well plates, were incubated for 24 h in serumfree DMEM medium containing 2 ,Ci/ml of 3H-inositol then placed in a HEPES-buffered DMEM (20 mM HEPES, pH 7.4). LiCl (20 mM) and agonists were added for the indicated time. The reaction was stopped by adding 10 mM HCOOH, and the level of total inositol phosphates was measured by anion exchange chromatography and liquid scintillation counting as previously described (Seuwen et al., 1988a) .
Measurement of Adenylate Cyclase Activity
Quiescent cells in 12-well plates prelabeled for 24 h with 2 MCi/mI of 3H-adenine were incubated in a HEPES-buffered DMEM (20 mM HEPES, pH 7.4) containing 1 mM isobutylmethylxanthine to inhibit phosphodiesterase activity. Forskolin (50 MM) and agonists were added for the indicated time. In the case of pertussis toxin pretreated cells, the toxin was added during the last 5 h of prelabelling. The reaction was stopped after 5 min by adding 5% ice-cold trichloroacetic acid. 3H-ATP and 3H-cAMP were separated by sequential chromatography on Dowex and alumina columns (Bio-Rad, Paris, France) as described .
Measurement of DNA Synthesis
Quiescent cells in 24-well plates were stimulated for 24 h by different agonists in a serum-free DMEM/Ham's F12 medium (1:1) containing 3H-thymidine (1 MCi/ml; 3 MM) and 10 Mug/ml fatty acd-free bovine serum albumin. 3H-thymidine incorporated into trichloroacetic acidprecpitable material was recovered with 0.1 N NaOH and quantitated by liquid scintillation counting.
RESULTS

Comparison of Hamster and Human Thrombin Receptor Peptide Agonist Sequences
The predicted amino acid sequence of a human thrombin receptor (Vu et al., 1991) shares 79% overall sequence identity with the Chinese hamster thrombin receptor homolog (Rasmussen et al., 1991) . Both receptors possess a similar consensus thrombin cleavage site in the extracellular N-terminal region as well as a nearby stretch of acidic residues that potentially interact with thrombin's "anion-binding exosite." Alignment of hamster and human receptor sequences surrounding the putative cleavage site (R-41-S-42) and extending through the negative charge cluster region is shown in Figure 1 . The hamster and human receptor sequences differ by only one amino acid (F to L in position 44) in the first seven residues carboxyl to R-41. Thereafter, the two receptor sequences diverge and a gap of three amino acids must be introduced in the human sequence to align the negatively charged domain and subsequent receptor sequences. In light of this sequence comparison, we initially compared the ability of synthetic peptides corresponding to the sequence of the cloned hamster thrombin receptor (just downstream from the putative thrombin cleavage site) with that of human receptor peptides to activate human thrombin receptors. Thrombin is one of the most potent and physiologically significant activators of platelets, causing secretion and aggregation at subnanomolar concentrations. Activation of human platelets by thrombin and receptor peptides, measured by 14C-serotonin release, is shown in Figure   2 . Both thrombin and receptor peptide agonists induced the same maximal levels of 1"C-serotonin release, indicating that the peptides behave as full receptor agonists in this bioassay. The 14-residue peptide (SFLLRNPNDKYEPF) described in the human receptor study and the corresponding 7 N-terminal residues from the hamster receptor sequence (SFFLRNP) were equipotent for platelet activation (EC50 = 3 MM) consistent with their high homology. The 14-residue hamster receptor peptide (SFFLRNPGENTFEL) stimulated 14C-serotonin release less potently than its human receptor counterpart, with an EC50 of -10 AM.
Activation of Phospholipase C by Thrombin Receptor Peptides
To further analyze the "tethered ligand" hypothesis and to identify the intracellular effectors that may be modulated by the thrombin receptor, we examined the effect of the human and hamster receptor peptides on cultured CCL39 hamster fibroblasts. Because the cloned receptor activates Ca2" mobilization in Xenopus oocytes (Van Obberghen-Schilling et al., 1990; Rasmussen et al., 1991; Vu et al., 1991) , the ability of peptides to activate phospholipase C was analyzed. As shown in Figure 3A , addition of peptides corresponding to the sequence of 14 residues after the putative thrombin cleavage site in the hamster receptor activates phospholipase C. In fact, the first seven N-terminal residues stimulate inositol phosphate release more effectively than the 14-mer, with half maximal stimulation achieved with =20 MM peptide. The 7-mer at a concentration of 30 MM was as effective as 100 nM thrombin in stimulating initial rates of inositol phosphate formation. We have previously reported that the initial rate of thrombin-stimulated inositol phosphate formation attenuates rapidly, and this desensitization occurs at the receptor level (L' Allemain et al., 1986; Paris et al., 1988) . To determine whether both the peptide agonists and thrombin elicit a similar degree of desensitization, we compared the effect of thrombin and receptor 7-mer on phosphoinositide breakdown. Figure 3B shows that 10 MM of hamster receptor 7-mer and 1 nM thrombin, concentrations that induce equivalent phospholipase C activation, induce comparable desensitization (T1/2 = 5 min). After 1 h of treament with thrombin or receptor peptide, only 30% residual activity was observed for both agonists.
Importantly, 1 h pretreatment of cells with thrombin blunted activation of phospholipase C by the 7-mer (45% residual activity), whereas thrombin or 7-mer pretreatment of cells for 1 h had no effect on activation of phospholipase C by serotonin which acts via the 5-HT2 receptor subtype in CCL39 cells (Seuwen et al., 1988b . This mitogenic effect of thrombin can be blocked (z95%) by pertussis toxin (Chambard et al., 1987) , suggesting the involvement of one or more pertussis toxin-sensitive G protein-coupled pathways. To determine whether the receptor peptides could mimic the mitogenic action of thrombin, we compared the effect of thrombin and receptor peptide agonists on stimulation of DNA synthesis in CCL39 cells. In contrast to thrombin, peptides (7-or 14-mer) at concentrations up to 300 ,uM have no detectable effect on 3H-thymidine incorporation ( Figure 5 ). However, both peptides potentiate the mitogenic effect of FGF acting through its _j tyrosine kinase receptor ( Figure 5 ). This is consistent 10 with our previous work showing that activation of G protein-coupled pathways potentiates the mitogenic action of FGF in CCL39 cells (Seuwen et al., 1988b;  ulation of phospholipase C, receptor peptides could modulate adenylate cyclase activity. Figure 4 presents the dose response of hamster 7-and 14-mer peptide agonists on 3H-cAMP formation stimulated by forskolin. Both the 7-and 14-mer peptides were as effective as thrombin, which produced maximal values of up to 40% inhibition. Once again, the 7-residue peptide was more potent than the 14-residue peptide, with EC50 values of <3 and 10 ,uM, respectively. Similar to thrombin, the inhibitory effect of the peptides was alleviated by pertussis toxin pretreatment of the cells (Figure 4) Paris and Pouyssegur, 1990; Seuwen et al., 1990b) . In addition, potentiation to a similar extent of the mitogenic action of other growth factors with tyrosine kinase receptors, including platelet-derived growth factor (PDGF), insulin, and epidermal growth factor, was observed with the receptor peptides. Stimulation by thrombin, however, was not altered in presence of the peptides. In this assay, as opposed to the rapid biochemical assays described above, the 14-mer appeared to be more potent than the 7-mer with EC50 values of a20 and 30 ,iM, respectively. The human 14-mer was as potent as the hamster 14-mer in its ability to stimulate thymidine incorporation into DNA, as seen for stimulation of the 14C-serotonin release in human platelets (Figure 1 ). Pertussis toxin inhibited the effect of receptor peptides by '30% without affecting FGF-stimulated DNA synthesis. The lack of effect of peptides alone can not be attributed to peptide degradation because replacement of the medium with fresh medium containing peptide did not alter the results with peptides alone or in the presence of FGF. Furthermore, incubation of the peptides in the presence of cells for 4 h did not significantly diminish their ability to stimulate phospholipase C.
Minimal Length of Active Receptor Peptides
To assess the minimum functional unit required for thrombin receptor activation, we tested the effect of peptides of varying lengths on the cellular events described above. Vu et al. (1991) showed that removal of the two N-terminal residues SF, or their inversion to FS, rendered the human receptor 14-mer inactive. Therefore, the N-terminus appeared to be required for receptor activation by peptides. We found that the dipeptide SF (with a C-terminal amide) had no effect on phospholipase C (Figure 6 ) or adenylate cyclase at concentrations up to 300 ,M. In addition, we tested peptides ranging from three to six residues corresponding to the hamster receptor sequence (with free carboxyl termini). As shown in Figure 6 , at a given peptide concentration (10 ,M), the 6-mer was as effective as the 7-mer in stimulation of phospholipase C. Phospholipase C activation by the 5-mer was markedly lower; moreover, peptides with four residues or less were inactive. A similar pattern was observed for peptide activation of a pertussis toxin-sensitive pathway as measured by inhibition of adenylate cyclase. Dose responses of the peptides for potentiation of FGF-stimulated DNA synthesis is pictured in Figure 7A . With decreasing peptide size, the EC50 shifted from n~30
,uM for the 7-mer to 75 and -150 gM for the 6-and 5-mers, respectively. Receptor peptides of less than five residues failed to synergize with FGF for DNA synthesis stimulation at the concentrations shown. We were unable to further increase the concentrations of 3-and 4-mers in the assay due to their limited solubility. Interestingly, a similar pattern was observed for activation of human platelets by the hamster receptor peptides ( Figure 7B ), including the fact that at least five residues were required for bioactivity. In platelets, however, the six-and seven-residue peptides were equipotent (EC50 3 ,uM) and more active than the 14-mer.
DISCUSSION
For several years, studies from our laboratory have addressed the role of thrombin in growth control (for reviews, see Pouyssegur et al., 1988; Pouyssegur and Seuwen, 1991 (Seuwen et al., 1988b; Paris and Pouyssegur, 1990; Seuwen et al., 1990b) . This effect has largely been attributed to activation of a "Gi pathway" (Seuwen et al., 1988b; Seuwen et al., 1990b ), yet a contribution from the phospholipase C/protein kinase C pathway is appreciable (Van Obberghen-Schilling et al., 1991) . The use of synthetic receptor peptides has allowed us to assess the role of G protein-coupled pathways activated by the cloned thrombin receptor in growth stimulation. Our finding that receptor peptide agonists are not mitogenic on their own further supports the idea 100 that even strong activation of phospholipase C alone (Seuwen et al., 1990a) or together with Gi-coupled pathways is not sufficient for cell cycle re-entry of quiescent cells (Van Obberghen-Schilling et al., 1991) . This suggests that the potent mitogenic action of thrombin results from the activation of multiple cooperating signaling pathways, including a yet unidentified pathway likely to involve tyrosine kinase(s) activation.
Tyrosine kinase activation by thrombin may be mediated directly by an unidentified thrombin receptor with intrinsic tyrosine kinase activity or association of a transmembrane receptor devoid of kinase activity with a cytoplasmic tyrosine kinase, as is the case for CD4 associated with a member of the src family (Ick) through its cytoplasmic tail (Veillette et al., 1989) . Thrombin binding sites (Kd = 2 nM) of 150 kDa have been identified on the surface of hamster fibroblasts (Moss et al., 1983; by affinity labeling. At least in CCL39 cells, these "silent receptors" do not appear to directly mediate thrombin's mitogenic effects , although they may contribute to thrombin action in some cooperative fashion. Indeed, thrombin has been shown to activate phosphorylation on tyrosine residues of a number of cellular proteins in platelets (Ferrell and Martin, 1988; Golden and Brugge, 1989) and in CCL39 cells (Kohno and Pouyssegur, 1986) . We are currently comparing the ability of thrombin and receptor peptides to induce tyrosine phosphorylation in CCL39 fibroblasts. It is also possible that in addition to its own receptor, thrombin cleaves another growth factor receptor, which leads to tyrosine phosphorylation by indirect activation of tyrosine kinase(s) or inhibition of tyrosine phosphatase(s). Finally, thrombin could stimulate autocrine production of a growth factor, which in turn functions synergistically with thrombin. For example, it is known that thrombin induces production of PDGF-like molecules by endothelial cells (Harlan et al., 1986) . Whatever the mechanism may be by which thrombin activates DNA synthesis, it involves a pertussis toxin-sensitive limiting step (Chambard et al., 1987) . The data presented above provide further evidence that a thrombin receptor ligand resides in the N-terminal sequence of the receptor and thrombin cleavage initiates receptor coupling to G proteins. The fact that desensitization of the phospholipase C response by thrombin and synthetic receptor peptides is both reciprocal and homologous strengthens the hypothesis that the peptides stimulate the receptor, as opposed to directly activating G proteins as does the 14-residue peptide mastoparan (Higashijima et al., 1988) . Because we observed concomitant activation of phospholipase C and inhibition of adenylate cyclase with the same synthetic peptides, several possible scenarios of receptor/G protein/effector coupling systems can be considered. The cloned human and hamster receptor sequences may be capable of interacting with more than one G protein (a "Gq" and Gi) (for review, see Simon et al., 1991) , or the G protein with which the receptor interacts may activate more than one effector. In situations where the same receptor subtype couples to both adenylate cyclase and phosphoinositide tumover (e.g., the muscarinic m2 [Ashkenazi et al., 1987] , serotonin 5-HT1A [Fargin et al., 1989] nitude lower than those required for activation of phospholipase C. However, this difference does not necessarily reflect the presence of separate receptor isoforms. Studies using the transfected cDNA clone to address this issue are hampered by the fact that endogenous thrombin receptors, or the thrombin inhibitor protease nexin I (Knauer and Cunningham, 1984) , are expressed by all of the cell types that we have examined to date. Experiments with genetically engineered receptor mutants, modified in the thrombin cleavage site, are currently in progress to circumvent this problem.
We observed that shorter peptides (of 6 and 7 residues) are more potent than 14-residue peptides in stimulating rapidly measured events (serotonin release, activation of phospholipase C, and inhibition of adenylate cyclase) than reinitiation of DNA synthesis. This may be due to differences in peptide stability throughout the duration of the assays or to the fact that residues from the negative charge cluster are present in the 14-mer that may influence the binding and/or receptor activation properties of the receptor ligand.
It is tempting to suggest that the N-terminal fragment released from the receptor after thrombin cleavage has a physiological role. However, in preliminary studies we have not detected a stimulatory effect of the fragment released from the hamster thrombin receptor that was generated by treating CCL39 cells with thrombin, then blocking the thrombin with an excess of hirudin. Furthermore, a synthetic peptide corresponding to the human receptor sequence between the putative signal peptide and thrombin cleavage site is without effect in CCL39 cells. Sequence homology is not very high between the human and hamster receptors in this region (Rasmussen et al., 1991) , and the exact site of signal peptidase cleavage has not yet been established in either the human or hamster receptor sequence. Use of antibodies to isolate and follow the fate of the released fragment should help to clarify this point.
In conclusion, cDNA cloning of a seven-transmembrane-domain thrombin receptor has provided access to the molecular mechanism of thrombin action. Questions have been raised by many investigators for several years concerning the nature of thrombin's interaction with its target cells. It now seems clear that both proteolytic cleavage and receptor-mediated G protein activation occur, yet it remains to be determined where the receptor-ligand binding site lies in the "transmembrane barrel" of the thrombin receptor. The observation that synthetic peptides have potent cellular effects should lead to the design of targeted receptor agonists and antagonists that bypass thrombin action in the coagulation cascade.
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